Biotechnology

The International Society for Pharmaceutical Engineering has announced the 2021 Facility of the Year Awards category winners. The awards include:

Life sciences developer IQHQ began construction in April of 2021 on the $1 billion Fenway Center in Boston. Created in collaboration with Meredith Management, the biomedical research hub will be situated over the Massachusetts Turnpike on an air rights deck. The amenity-rich campus will include two towers offering 960,000 sf of leasable lab and office space, 10,000 sf of ground-floor retail, and an automated parking garage.

Promega Corporation opened the 283,000-sf Kornberg Center in April of 2021 in Fitchburg, Wis. Designed by Ramlow/Stein and SmithGroup, the three-story facility provides advanced laboratories for core product and technology development in cellular and molecular biology, biochemistry, genetic identity, clinical diagnostics, and scientific applications.

Arizona State University and Wexford Science+Technology opened the PBC Innovation Center on the Phoenix Biomedical Campus in March of 2021. Strategically collocating academic investigators with private companies to foster collaboration and discovery, the 225,000-sf facility provides wet and dry lab environments, offices, meeting spaces, and retail amenities.

Brandywine Realty Trust began construction in March of 2021 on the $287 million West Tower at Schuylkill Yards in Philadelphia. The 28-story, 570,000-sf structure will provide 200,000 sf of laboratory and office space for biomedical and life sciences companies, as well as 9,000 sf of retail space and 326 luxury apartments. On the ninth floor, a 29,000-sf lifestyle club will offer a sophisticated fitness center, a swimming pool, lounges, conference rooms, and co-working venues.

Vibalogics is creating a 110,000-sf facility for the production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products in Boxborough, Mass. Supporting late-phase clinical and commercial manufacturing operations, the highly flexible structure will include 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control. The $150 million project involves the renovation of an existing R&D building previously occupied by Cisco Systems.

Boylston Properties and J.P. Morgan Asset Management began construction in January of 2021 on a 165,600-sf life sciences facility in Watertown, Mass. Located in the Arsenal Yards district, 100 Forge will be the first purpose-built laboratory building in the city. The joint venture development team has secured a $100.1 million construction loan for the project.

Civica Rx began construction in early 2021 on a $124.5 million pharmaceutical manufacturing center in Petersburg, Va. Created in collaboration with Phlow Corp., the 120,000-sf plant will produce sterile injectables for the treatment of COVID-19, emergency room and intensive-care unit treatments, surgeries, and other serious conditions. The facility will feature steam sterilization capabilities, disposable technologies, and advanced automation systems for visual inspection and packaging.

BioMed Realty is planning to create a life sciences innovation campus in Somerville, Mass. The project includes the renovation of an existing 162,000-sf office building and the construction of new facilities on an adjacent 7.5-acre parcel. Offering leasable environments for biomedical, pharmaceutical, and technology companies, the Assembly Square complex will provide 1.3 million sf of research, corporate, and retail space. The mixed-use development will feature multiple roof terraces and a one-acre public park. BioMed Realty acquired the property in early 2021.

Canadian developer Oxford Properties has expanded its real estate portfolio in the United States with the acquisition of four new assets. Representing an investment of $276 million in the burgeoning life sciences industry, the purchase included a total of 415,000 sf of existing space and associated developable land. Oxford Properties plans to spend an additional $500 million to repurpose, renovate, and expand the four structures to create leading-edge lab and office environments for biomedical tenants. 

Silverstein Properties & Cantor Fitzgerald are partnering with University Place Associates to create a biomedical innovation center in Philadelphia. Providing leading-edge lab and office facilities, 3.0 University Place is pre-certified as LEED Platinum v4 BD+C for core and shell, and will also target WELL Core v2 Platinum certification.

BioMed Realty is creating a 482,000-sf life sciences hub in Boston's Seaport District. Previously serving as the corporate headquarters of John Hancock, the building was acquired by BioMed Realty in late 2020. Featuring robust mechanical and electrical systems, the existing structure has attained LEED Platinum sustainable design certification and includes a variety of collaborative meeting areas. The facility will be renovated to provide sophisticated lab and office environments for biomedical companies. Occupancy is expected in the second half of 2022. 

Thermo Fisher Scientific is expanding its global production capacity for vaccines, medicines, and biologic therapies. Construction will begin in mid-2021 on a 130,000-sf facility in Greenville, N.C. Slated for completion in 2022, the standalone structure will accommodate two live-virus filling lines. The project is part of a $500 million investment in the site that will add six new lines in existing buildings to support commercial-scale liquid vial filling and the creation of lyophilized materials. 

Millennium Partners and Beacon Capital Partners will begin construction in late 2021 on a 380,000-sf life sciences facility in Boston. Designed by Handel Architects in collaboration with STUDIO ENÉE, the mixed-use development will provide leading-edge laboratories, offices, and R&D suites clustered around a collaborative open space. Located on 4.6 acres in the Raymond L. Flynn Marine Park, the eight-story project will feature a central core of corrugated metal to celebrate the area's industrial heritage.

Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio. The 185,000-sf facility will enable Andelyn Biosciences, a for-profit subsidiary of Nationwide Children's, to supply pharmaceutical and biotechnology companies with genetic material for use in research and clinical trials. Located in The Ohio State University's Innovation District, the leased structure will feature advanced cGMP environments for commercial-scale manufacturing.